Menu
Recruiting NCT00901602

Lebanese Interhospital Pneumococcal Surveillance Program

Observational Pneumonia Meningitis Sepsis Bacteremia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Pneumonia, Meningitis, Sepsis, Bacteremia. Basic parameters: from 1 Day · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Lebanon
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Lebanese Interhospital Pneumococcal Surveillance Program (LIPSP)

Overview

Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection. There are many types of these bacteria defined by the type of sugar coat that they have. These are classified as serotypes. There are common serotypes that cause severe disease and are preventable by vaccination of children. Other less common types are more difficult to prevent. The investigators aim to determine the serotypes that cause invasive pneumococcal disease in Lebanon and to study their sensitivity to different antibiotics. The investigators will collect bacterial isolates from different hospitals in Lebanon isolated from the blood or spinal fluid of patients with invasive pneumococcal disease. This information will help the investigators determine the usefulness of available pneumococcal vaccines in preventing these infections. The data will be distributed to all primary care physicians treating children in Lebanon and will be shared with the Ministry of Health.

Primary outcome measures

  • Serotype prevalence of S. pneumoniae in invasive pneumococcal disease [Time frame: yearly]
Secondary outcome measures (1)
  • Determine the antibiotic sensitivity of S. pneumoniae and the association with specific serotypes [Time frame: yearly]

Eligibility criteria

Inclusion criteria

  • Samples included in the study are those that are:
  • culture proven
  • invasive pneumococcal infections
  • in patients of all ages admitted to different hospitals all over Lebanon
  • Acceptable samples include:
  • positive isolates from blood
  • cerebrospinal fluid
  • other normally sterile body sites such as empyema fluid, abscesses, joint fluid, middle ear fluid obtained by tympanocentesis in the operating room, and lung needle aspiration

Exclusion criteria

  • non S. pneumoniae isolates

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-only

Study locations

Lebanon · 1 center
  • American University of Beirut — Beirut

Identifiers

NCT: NCT00901602 · PNEUMOSurv1LIPSP

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗